Exagen (XGN)
(Delayed Data from NSDQ)
$1.41 USD
0.00 (0.15%)
Updated Apr 26, 2024 03:50 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
XGN 1.41 0.00(0.15%)
Will XGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for XGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XGN
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
Cresco Labs Inc. (CRLBF) Q4 Earnings and Revenues Surpass Estimates
XGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zynex Inc. (ZYXI) Q4 Earnings and Revenues Miss Estimates
Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
Other News for XGN
Exagen Inc. Announces Changes to the Board of Directors
Exagen Inc Board Reshuffle and New Class I Director Appointment
Exagen to reduce size of board to seven from nine
Wall Street Analysts Are Bullish on Top Healthcare Picks
Buy Rating Affirmed for Exagen on Strong Financials and Strategic Growth Initiatives